Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes... Show more
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX), formerly known as OncoCyte Corporation, is a precision diagnostics company headquartered in Nashville, Tennessee. The company develops and commercializes molecular diagnostic tests, with a near-term strategic focus on organ transplant rejection monitoring. Its GraftAssure platform quantifies donor-derived cell-free DNA (dd-cfDNA), a biomarker used to assess the probability of transplanted organ rejection.
The company's portfolio includes GraftAssureCore, a laboratory-developed test reimbursed by CMS and performed at its CLIA-certified laboratory; GraftAssureIQ, a research-use-only (RUO) kit; and GraftAssureDx, an in vitro diagnostic (IVD) kit currently in development. IMDX's "decentralized" business model is designed to place testing in local hospital and transplant-center labs rather than relying on a central send-out model. A global strategic partnership with Bio-Rad Laboratories underpins the platform, using Bio-Rad's digital PCR instruments and reagents.
Over the last 30 days, IMDX declined from a closing price of approximately $3.02 on October 21, 2026, to roughly $1.86 in late November, a drop of about 38%. The selloff was broad-based but intensified in mid-November, when the stock broke decisively below the $2 level.
The quarterly picture is even steeper. From a closing level near $4.30 in late August, the stock has fallen roughly 57% to recent levels. This places IMDX well below its 52-week high of $7.51, with the shares trading in the lower portion of their 52-week range of roughly $1.50 to $7.51.
The most direct catalyst was the company's November 16, 2026, announcement of a proposed underwritten public offering of common stock and pre-funded warrants. Equity offerings that increase the outstanding share count are typically viewed as dilutive to existing holders, and the announcement coincided with a sharp leg lower in the shares.
Beyond the offering, the stock had already been under sustained selling pressure. IMDX operates with a relatively small revenue base and continues to report operating losses, which leaves the company reliant on external capital. This combination of capital-raising needs, ongoing cash burn, and limited near-term revenue visibility contributed to negative sentiment throughout the period, particularly as broader risk appetite for small- and micro-cap biotech names remained subdued.
The quarterly decline reflects a longer-running transition in the company's strategy. IMDX has been shifting its focus away from legacy oncology laboratory-developed tests toward its GraftAssure transplant franchise and kitted-product model. In its 2025 annual report, the company disclosed a $14.6 million impairment of its DetermaIO and DetermaCNI intangible assets during the fourth quarter of 2025, underscoring the move away from those oncology programs.
At the same time, the company's modest reported revenue and negative earnings have kept it dependent on periodic financings, which weigh on the share price. Investors have been weighing the long-term opportunity in transplant diagnostics against the near-term reality of high cash burn and dilution risk, and the stock has drifted lower over the quarter as a result.
Tickeron operates a platform of hundreds of AI-powered trading bots that collectively monitor thousands of tickers across different strategies, timeframes, and performance metrics. Rather than presenting every available bot, the Trending AI Robots section curates only the top-performing and most relevant strategies, making it easier for users to identify approaches that are currently standing out. Because the bots vary widely in methodology and holding period, the page offers a useful starting point for those researching systematic, data-driven trading ideas. Investors interested in exploring how AI-driven strategies are performing can review the curated selection on the Trending AI Robots page.
Looking ahead, the most important near-term factor is the completion and pricing of the proposed public offering, including the final number of shares issued and the intended use of proceeds, as these will shape dilution and cash runway. Investors should also monitor commercial progress on GraftAssureIQ kitted sales and the development timeline for GraftAssureDx, which represents the company's clinical IVD opportunity.
Additional factors include the pace of revenue growth, the company's cash position and ability to fund operations, CMS reimbursement dynamics for GraftAssureCore, and the competitive landscape in transplant diagnostics. Broader conditions in the biotech and diagnostics sector, as well as overall risk sentiment toward small-cap equities, may also influence the stock's direction.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IMDX saw its Momentum Indicator move below the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned negative. In 84 of the 91 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for IMDX turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 47 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IMDX entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMDX's RSI Oscillator exited the oversold zone, 30 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +23.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMDX advanced for three days, in 166 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
IMDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.826) is normal, around the industry mean (67.298). P/E Ratio (-1.638) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. IMDX's P/S Ratio (71.942) is very high in comparison to the industry average of (9.775).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. IMDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of ovel, non-invasive, liquid biopsy diagnostics for the early detection of cancer
Industry MedicalSpecialties